Matchpoint Therapeutics
James Holland, CPA, currently serves as the Controller and Senior Director of Finance at Matchpoint Therapeutics since May 2023. Previously, James held the position of Assistant Controller at Repligen Corporation from June 2021 to May 2023. James's extensive experience includes a three-year tenure as Managing Director and Senior Manager at CFGI, a specialized financial consulting firm that provides various corporate finance services. Prior roles also include Senior Manager and Manager at KPMG US from July 2011 to November 2018. James holds a Master’s degree in Accounting from Suffolk University.
This person is not in any teams
This person is not in any offices
Matchpoint Therapeutics
Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning, and covalent chemistry libraryevolution. Matchpoint has an emerging pipeline of novel covalent medicines, initially focused on immunology.